Source:http://linkedlifedata.com/resource/pubmed/id/14504078
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-12-19
|
| pubmed:abstractText |
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of DLBCL, 142 of which had been successfully evaluated by cDNA microarray (75 GCB, 41 ABC, and 26 type 3). Sections were stained with antibodies to CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2. Expression of bcl-6 (P <.001) or CD10 (P =.019) was associated with better overall survival (OS), whereas expression of MUM1 (P =.009) or cyclin D2 (P <.001) was associated with worse OS. Cases were subclassified using CD10, bcl-6, and MUM1 expression, and 64 cases (42%) were considered GCB and 88 cases (58%) non-GCB. The 5-year OS for the GCB group was 76% compared with only 34% for the non-GCB group (P <.001), which is similar to that reported using the cDNA microarray. Bcl-2 and cyclin D2 were adverse predictors in the non-GCB group. In multivariate analysis, a high International Prognostic Index score (3-5) and the non-GCB phenotype were independent adverse predictors (P <.0001). In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ArmitageJames OJO,
pubmed-author:BanhamAlison HAH,
pubmed-author:BrazielRita MRM,
pubmed-author:ChanWing CWC,
pubmed-author:ConnorsJoseph MJM,
pubmed-author:DelabieJanJ,
pubmed-author:FaliniBrunangeloB,
pubmed-author:FarinhaPedroP,
pubmed-author:GascoyneRandy DRD,
pubmed-author:GreinerTimothy CTC,
pubmed-author:HansChristine PCP,
pubmed-author:JaffeElaine SES,
pubmed-author:KochM FMF,
pubmed-author:Müller-HermelinkH KonradHK,
pubmed-author:OttGermanG,
pubmed-author:PanZenggangZ,
pubmed-author:RosenwaldAndreasA,
pubmed-author:SmithLynette MLM,
pubmed-author:StaudtLouis MLM,
pubmed-author:WeisenburgerDennis DDD
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
275-82
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:14504078-Adolescent,
pubmed-meshheading:14504078-Adult,
pubmed-meshheading:14504078-Aged,
pubmed-meshheading:14504078-Aged, 80 and over,
pubmed-meshheading:14504078-Cyclin D2,
pubmed-meshheading:14504078-Cyclins,
pubmed-meshheading:14504078-Female,
pubmed-meshheading:14504078-Humans,
pubmed-meshheading:14504078-Immunohistochemistry,
pubmed-meshheading:14504078-Lymphoma, B-Cell,
pubmed-meshheading:14504078-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:14504078-Male,
pubmed-meshheading:14504078-Middle Aged,
pubmed-meshheading:14504078-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:14504078-Prognosis,
pubmed-meshheading:14504078-Protein Array Analysis,
pubmed-meshheading:14504078-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:14504078-Sensitivity and Specificity
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
|
| pubmed:affiliation |
Department of Pathology and Microbiology,University of Nebraska Medical Center, Omaha, NE 68198, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|